(19)
(11) EP 4 540 376 A2

(12)

(88) Date of publication A3:
08.02.2024

(43) Date of publication:
23.04.2025 Bulletin 2025/17

(21) Application number: 23824718.3

(22) Date of filing: 08.06.2023
(51) International Patent Classification (IPC): 
C12N 9/22(2006.01)
C12N 15/85(2006.01)
C07K 14/47(2006.01)
C12N 7/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 9/22; C12N 15/102; C12N 15/86; C12N 2750/14143
(86) International application number:
PCT/US2023/068149
(87) International publication number:
WO 2023/244934 (21.12.2023 Gazette 2023/51)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 15.06.2022 US 202263352494 P

(71) Applicant: Acrigen Biosciences, Inc.
Kensington, CA 94708 (US)

(72) Inventors:
  • RABUKA, David
    Kensington, California 94708 (US)
  • SHARRAR, Allison
    Berkeley, California 94710 (US)
  • DE TACCA, Luisa Mayumi Arake
    Albany, California 94706 (US)
  • SHELLE, Michael
    San Francisco, California 94102 (US)

(74) Representative: Glawe, Delfs, Moll 
Partnerschaft mbB von Patent- und Rechtsanwälten Postfach 13 03 91
20103 Hamburg
20103 Hamburg (DE)

   


(54) ENGINEERED ACR PROTEINS FOR MODULATING CRISPR ACTIVITY